Perrigo Company plc (NYSE:PRGO) Shares Bought by Nicola Wealth Management LTD.

Nicola Wealth Management LTD. raised its position in Perrigo Company plc (NYSE:PRGO - Free Report) by 164.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,000 shares of the company's stock after acquiring an additional 56,000 shares during the quarter. Nicola Wealth Management LTD. owned approximately 0.07% of Perrigo worth $2,896,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC acquired a new position in Perrigo in the 4th quarter valued at about $30,000. Parkside Financial Bank & Trust boosted its stake in shares of Perrigo by 1,694.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,041 shares of the company's stock valued at $34,000 after buying an additional 983 shares during the period. Hexagon Capital Partners LLC purchased a new position in shares of Perrigo in the 4th quarter valued at about $37,000. Blue Trust Inc. boosted its stake in shares of Perrigo by 34.5% in the 4th quarter. Blue Trust Inc. now owns 1,556 shares of the company's stock valued at $50,000 after buying an additional 399 shares during the period. Finally, Fifth Third Bancorp boosted its stake in shares of Perrigo by 39.5% in the 3rd quarter. Fifth Third Bancorp now owns 1,714 shares of the company's stock valued at $55,000 after buying an additional 485 shares during the period. 95.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Piper Sandler lifted their price objective on Perrigo from $35.00 to $39.00 and gave the company an "overweight" rating in a research note on Monday, April 8th. JPMorgan Chase & Co. decreased their price objective on Perrigo from $48.00 to $41.00 and set an "overweight" rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group reiterated a "buy" rating and issued a $42.00 price objective on shares of Perrigo in a research note on Friday, April 12th. Finally, StockNews.com upgraded Perrigo from a "hold" rating to a "buy" rating in a research note on Thursday.

Perrigo Stock Down 0.9 %

PRGO stock traded down $0.27 during trading on Friday, hitting $29.83. 1,273,145 shares of the company's stock were exchanged, compared to its average volume of 1,767,981. The business has a 50-day moving average price of $31.15 and a two-hundred day moving average price of $31.01. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -426.14 and a beta of 0.63. Perrigo Company plc has a 52-week low of $25.77 and a 52-week high of $40.28. The company has a current ratio of 1.81, a quick ratio of 1.08 and a debt-to-equity ratio of 0.77.

Perrigo (NYSE:PRGO - Get Free Report) last posted its earnings results on Saturday, May 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a positive return on equity of 6.96% and a negative net margin of 0.17%. The firm's revenue was down 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.45 earnings per share. As a group, equities research analysts expect that Perrigo Company plc will post 2.57 EPS for the current year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Friday, May 31st will be given a dividend of $0.276 per share. This represents a $1.10 annualized dividend and a yield of 3.70%. The ex-dividend date of this dividend is Friday, May 31st. Perrigo's dividend payout ratio (DPR) is -1,571.43%.

Insiders Place Their Bets

In other news, EVP Alison Ives purchased 2,490 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the transaction, the executive vice president now directly owns 16,122 shares in the company, valued at approximately $439,485.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Robert Willis bought 6,000 shares of the company's stock in a transaction dated Thursday, February 29th. The shares were acquired at an average price of $25.87 per share, with a total value of $155,220.00. Following the completion of the acquisition, the executive vice president now owns 25,105 shares in the company, valued at approximately $649,466.35. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Alison Ives bought 2,490 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was bought at an average cost of $27.26 per share, for a total transaction of $67,877.40. Following the acquisition, the executive vice president now owns 16,122 shares of the company's stock, valued at approximately $439,485.72. The disclosure for this purchase can be found here. Insiders have bought a total of 17,990 shares of company stock valued at $475,227 over the last quarter. Company insiders own 0.70% of the company's stock.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.